Atlas Venture Life Science Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-76,979	Closed	-$2.11M	–	14
2024 Q3	$2.11M	Sell	76,979 -60,000	-44%	-$1.67M	0.2%	13
2024 Q2	$3.55M	Sell	136,979 -50,000	-27%	-$1.2M	0.37%	13
2024 Q1	$5.61M	Sell	186,979 -50,000	-21%	-$1.09M	0.52%	14
2023 Q4	$2.46M	Hold	236,979	–	–	0.29%	14
2023 Q3	$3.24M	Sell	236,979 -2	-0%	-$25	0.5%	14
2023 Q2	$2.87M	Hold	236,981	–	–	0.36%	14
2023 Q1	$3.01M	Buy	236,981 +19,697	+9%	+$218K	0.41%	14
2022 Q4	$1.37M	Hold	217,284	–	–	0.17%	17
2022 Q3	$4.9M	Hold	217,284	–	–	0.54%	13
2022 Q2	$4.17M	Hold	217,284	–	–	0.7%	12
2022 Q1	$10.1M	Hold	217,284	–	–	1.27%	11
2021 Q4	$15.4M	Buy	+217,284	New	+$21.8M	1.41%	12

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atlas Venture Life Science Advisors's DNTH Position: Q4 2024 in Review

Atlas Venture Life Science Advisors sold out of Dianthus Therapeutics (DNTH) in Q4 2024, closing a stake of 76,979 shares — an estimated $2.11M sold.

Atlas Venture Life Science Advisors first reported a position in DNTH in Q4 2021 and held it in 12 quarters. The position peaked at $15.4M in Q4 2021. 95 funds tracked by Wall St. Rank hold DNTH as of Q4 2024.

Atlas Venture Life Science Advisors reported no remaining Dianthus Therapeutics position as of Q4 2024 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 76,979 Dianthus Therapeutics shares in Q4 2024, an estimated $2.11M.
Atlas Venture Life Science Advisors first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 12 quarters.
Atlas Venture Life Science Advisors's Dianthus Therapeutics position peaked at $15.4M in Q4 2021.
95 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2024.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.